The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jul 9

PMID 27388289

Citations 12

Authors

Qing Wang

Yi-Zhan Guo

Yi-Tao Zhang

Jiao-Jie Xue

Zhi-Chong Chen

Shi-Yao Cheng

Mao-De Ou

Kang-Lin Cheng

Wei-Jie Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary hypertension due to left heart disease (PH-LHD) is one of the most common forms of PH, termed group 2 PH. Atorvastatin exerts beneficial effects on the structural remodeling of the lung in ischemic heart failure. However, few studies have investigated the effects of atorvastatin on PH due to left heart failure induced by overload.

Methods: Group 2 PH was induced in animals by aortic banding. Rats (n = 20) were randomly divided into four groups: a control group (C), an aortic banding group (AOB63), an atorvastatin prevention group (AOB63/ATOR63) and an atorvastatin reversal group (AOB63/ATOR50-63). Atorvastatin was administered for 63 days after banding to the rats in the AOB63/ATOR63 group and from days 50 to 63 to the rats in the AOB63/ATOR50-63 group.

Results: Compared with the controls, significant increases in the mean pulmonary arterial pressure, pulmonary arteriolar medial thickening, biventricular cardiac hypertrophy, wet and dry weights of the right middle lung, percentage of PCNA-positive vascular smooth muscle cells, inflammatory infiltration and expression of RhoA and Rho-kinase II were observed in the AOB63 group, and these changes concomitant with significant decreases in the percentage of TUNEL-positive vascular smooth muscle cells. Treatment of the rats in the AOB63/ATOR63 group with atorvastatin at a dose of 10 mg/kg/day significantly decreased the mean pulmonary arterial pressure, right ventricular hypertrophy, pulmonary arteriolar medial thickness, inflammatory infiltration, percentage of PCNA-positive cells and pulmonary expression of RhoA and Rho-kinase II and significantly augmented the percentage of TUNEL-positive cells compared with the AOB63 group. However, only a trend of improvement in pulmonary vascular remodeling was detected in the AOB63/ATOR50-63 group.

Conclusions: Atorvastatin prevents pulmonary vascular remodeling in the PH-LHD model by down-regulating the expression of RhoA/Rho kinase, by inhibiting the proliferation and increasing the apoptosis of pulmonary arterial smooth muscle cells, and by attenuating the inflammation of pulmonary arteries.

Citing Articles

Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.

Muehlebach M, Holstein S Clin Transl Med. 2023; 13(1):e1167.

PMID: 36650113 PMC: 9845123. DOI: 10.1002/ctm2.1167.

Animal models of pulmonary hypertension due to left heart disease.

Liu S, Yan Y Animal Model Exp Med. 2022; 5(3):197-206.

PMID: 35234367 PMC: 9240728. DOI: 10.1002/ame2.12214.

Inhibiting pyruvate kinase muscle isoform 2 regresses group 2 pulmonary hypertension induced by supra-coronary aortic banding.

Xiong P, Motamed M, Chen K, Dasgupta A, Potus F, Tian L Acta Physiol (Oxf). 2022; 234(2):e13764.

PMID: 34978755 PMC: 8810721. DOI: 10.1111/apha.13764.

The potential of Atorvastatin for chronic lung diseases therapy.

Tulbah A Saudi Pharm J. 2020; 28(11):1353-1363.

PMID: 33250642 PMC: 7679442. DOI: 10.1016/j.jsps.2020.08.025.

Mechanical stretching of pulmonary vein stimulates matrix metalloproteinase-9 and transforming growth factor-β1 through stretch-activated channel/MAPK pathways in pulmonary hypertension due to left heart disease model rats.

Zhang H, Huang W, Liu H, Zheng Y, Liao L PLoS One. 2020; 15(9):e0235824.

PMID: 32881898 PMC: 7470280. DOI: 10.1371/journal.pone.0235824.

References

Oka M, Fagan K, Jones P, McMurtry I . Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol. 2008; 155(4):444-54. PMC: 2579659. DOI: 10.1038/bjp.2008.239. View

Rhodes C, Davidson A, Gibbs J, Wharton J, Wilkins M . Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther. 2008; 121(1):69-88. DOI: 10.1016/j.pharmthera.2008.10.002. View

Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M . The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(3):195-206. DOI: 10.1007/s00210-006-0112-z. View

Sola S, Mir M, Lerakis S, Tandon N, Khan B . Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47(2):332-7. DOI: 10.1016/j.jacc.2005.06.088. View

Montalescot G, Drobinski G, Meurin P, Maclouf J, Sotirov I, Philippe F . Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998; 82(6):749-55. DOI: 10.1016/s0002-9149(98)00439-1. View

Bussotti M, Montorsi P, Amato M, Magini A, Baldassarre D, Tantardini F . Sildenafil improves the alveolar-capillary function in heart failure patients. Int J Cardiol. 2007; 126(1):68-72. DOI: 10.1016/j.ijcard.2007.03.118. View

Duan S, Zhang Y, Wu S, Jiang L, Zhang J, Gan Y . Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits. Exp Lung Res. 2010; 36(10):573-92. DOI: 10.3109/01902141003739715. View

Lewis G, Shah R, Shahzad K, Camuso J, Pappagianopoulos P, Hung J . Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007; 116(14):1555-62. DOI: 10.1161/CIRCULATIONAHA.107.716373. View

Guazzi M, Vicenzi M, Arena R, Guazzi M . PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2010; 4(1):8-17. DOI: 10.1161/CIRCHEARTFAILURE.110.944694. View

10.

Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I . Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. Cardiology. 2007; 109(4):273-80. DOI: 10.1159/000107791. View

11.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

12.

Dai Z, Wu B, Chen I, Chai C, Wu J, Chou S . Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. Pediatr Pulmonol. 2010; 46(1):45-59. DOI: 10.1002/ppul.21323. View

13.

Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D . Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2008; 294(4):H1804-14. DOI: 10.1152/ajpheart.01078.2007. View

14.

Jiang B, Tardif J, Sauvageau S, Ducharme A, Shi Y, Martin J . Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure. J Card Fail. 2010; 16(8):679-88. DOI: 10.1016/j.cardfail.2010.03.003. View

15.

Zhang M, Qu C, Zeng D . [The expression of Rho/Rho kinase of cardiac muscle in heart failure rats caused by pressure overload and the intervention of fasudil]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005; 33(1):73-6. View

16.

Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli W . Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011; 4(2):198-206. DOI: 10.1161/CIRCHEARTFAILURE.110.957050. View